BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, an oral once-daily inhibitor of Bruton's tyrosine kinase (BTK), has significantly improved progression-free survival (PFS) and overall survival (OS) in patients with chronic lymphocytic leukemia (CLL) [1].